Ofatumumab
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma
One-Sentence Summary
Ofatumumab is a fully human anti-CD20 monoclonal antibody whose efficacy is well established in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), though the drug is not currently marketed in Taiwan. The TxGNN model predicts it may also be effective for Follicular Lymphoma, a related CD20-positive B-cell malignancy, with 15 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — internationally established anti-CD20 indication; not yet approved in Taiwan |
| Predicted New Indication | Follicular Lymphoma |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L2 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information from the collected literature, ofatumumab is a fully human IgG1κ monoclonal antibody that binds a distinct small-loop epitope on the CD20 antigen, distinct from rituximab's binding site. It eliminates CD20-positive B cells primarily via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). This mechanism has been proven effective in CLL/SLL, where it is the drug's core, globally recognized indication.
Follicular lymphoma (FL) is, like CLL/SLL, a CD20-positive B-cell malignancy, meaning the same target antigen is expressed on the malignant cell population. This shared molecular target provides a direct mechanistic rationale for extending ofatumumab's use from CLL/SLL to FL — the same rationale that has already supported rituximab's dual approval across both diseases.
The strength of this prediction is reinforced by an unusually large clinical trial footprint: ofatumumab has been studied as monotherapy, in combination with CHOP, bendamustine, and bortezomib, and in radiotherapy-combination settings, across newly diagnosed, relapsed, and rituximab-refractory FL populations. While no Phase 3 confirmatory trial specific to FL exists yet, the depth of completed Phase 2 evidence (including a randomized Phase 2 trial) is substantial.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01294579 | Phase 2 | Completed | 49 | Ofatumumab + bendamustine followed by ofatumumab maintenance in indolent B-NHL relapsed after rituximab therapy |
| NCT01286272 | Phase 2 (Randomized) | Completed | 135 | Head-to-head: ofatumumab + bendamustine vs. ofatumumab + bendamustine + bortezomib in untreated FL |
| NCT00394836 | Phase 2 | Completed | 116 | International multicenter single-arm trial of ofatumumab monotherapy in rituximab-refractory FL |
| NCT00494780 | Phase 2 | Completed | 59 | Two-dose regimens of ofatumumab + CHOP in previously untreated FL |
| NCT01239394 | Phase 2 | Completed | 43 | Ofatumumab as initial systemic treatment for indolent B-cell lymphoma |
| NCT01190449 | Phase 2 | Completed | 51 | Ofatumumab monotherapy in previously untreated stage II–IV follicular NHL (CALGB) |
| NCT00742144 | Phase 1 | Completed | 6 | Japanese patients with CD20+ FL or CLL; PK/safety/tolerability profile |
| NCT02710643 | Phase 2 | Completed | 110 | MIRO trial: involved-field radiotherapy ± ofatumumab in stage I/II FL, Bcl-2-guided follow-up |
| NCT01263418 | Phase 2 | Withdrawn | 0 | Planned safety study in older patients with indolent NHL (FL/MZL); withdrawn before enrollment |
| NCT01397591 | Phase 2 | Terminated | 3 | Ofatumumab + bortezomib in relapsed CD20+ DLBCL/FL/MCL; terminated early, underpowered |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31174236 | 2019 | RCT | Cancer | CALGB 50904: randomized comparison of ofatumumab+bendamustine ± bortezomib in previously untreated high-risk FL |
| 22389254 | 2012 | Multicenter Study | Blood | Ofatumumab monotherapy in rituximab-refractory FL (n=116); ORR 13% |
| 30723894 | 2019 | Phase 2 Multicentre Trial | British Journal of Haematology | CALGB 50901: single-agent ofatumumab in untreated, low/intermediate-risk advanced-stage FL |
| 38937025 | 2024 | MRD-Driven Clinical Study | The Lancet Haematology | FIL MIRO trial final results: local radiotherapy ± ofatumumab in early-stage FL |
| 22409295 | 2012 | Phase 2 Combination Trial | British Journal of Haematology | Ofatumumab + CHOP (O-CHOP) as frontline treatment for FL, two-dose comparison |
| 24443277 | 2014 | Population PK Analysis | Journal of Clinical Pharmacology | Population pharmacokinetics of ofatumumab across CLL, FL, and rheumatoid arthritis |
| 28983798 | 2017 | Review | Advances in Therapy | 20-year review of anti-CD20 therapy (rituximab) across B-cell hematologic malignancies |
| 21083037 | 2010 | Review | Expert Review of Hematology | Emerging therapeutic strategies in follicular lymphoma |
| 35663281 | 2022 | Review | Leukemia Research Reports | Immunotherapy in indolent non-Hodgkin lymphoma, including FL |
| 18390837 | 2008 | Phase 1/2 Trial | Blood | First clinical use of ofatumumab in relapsed/refractory FL |
Taiwan Market Information
Ofatumumab is currently not marketed in Taiwan (0 licenses on record). No authorization data is available to summarize.
Cytotoxicity
Ofatumumab is included in this section as its established indication (CLL/SLL) is a hematologic malignancy, though it is a targeted biologic rather than a conventional cytotoxic chemotherapy agent.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy / Immunotherapy (anti-CD20 monoclonal antibody) |
| Myelosuppression Risk | Low–Moderate — neutropenia has been reported in CLL/FL trials, but this is distinct from classic cytotoxic-agent myelosuppression |
| Emetogenicity Classification | Low (monoclonal antibodies are generally minimally emetogenic) |
| Monitoring Items | CBC with differential, infusion-related reaction monitoring, hepatitis B screening (anti-CD20 reactivation risk), immunoglobulin levels |
| Handling Protection | Standard IV biologic infusion precautions with premedication; does not require cytotoxic chemotherapy handling protocols |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 2 trials — including a randomized Phase 2 study (NCT01286272/CALGB 50904) — consistently support ofatumumab's activity in follicular lymphoma, leveraging the same CD20-targeting mechanism already validated in its established CLL/SLL indication. However, no FL-specific Phase 3 confirmatory trial exists, and the drug is not currently marketed in Taiwan.
To proceed, the following is needed:
- TFDA/import registration pathway assessment, since ofatumumab has 0 current Taiwan authorizations
- Package insert warnings, contraindications, and DDI data (currently a Blocking data gap)
- Detailed mechanism of action documentation from DrugBank
- Confirmation of whether a Phase 3 FL-specific trial is planned or needed before market entry
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.